MASH: Survodutide improves Steatohepatitis and Fibrosis

被引：0
|
作者：
Krome, Susanne
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2025年 / 63卷 / 01期
关键词：
D O I：
10.1055/a-2392-2365
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is associated with increased morbidity and mortality. GLP-1 receptor agonists have a positive effect, but have no direct influence on the liver because hepatocytes lack GLP-1 receptors. Unidual agonism with the combination of GLP-1 and glucagon receptor agonism is said to improve the results. Survodutide has this dual agonistic function and met the endpoints in a double-blind parallel group study.
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [31] CYSTAMINE D4 IMPROVES LIVER INFLAMMATION AND FIBROSIS IN A MURINE MODEL OF FIBROSING STEATOHEPATITIS
    Leszczynska, Ola
    Kaufmann, Benedikt
    Alle, Thibault
    Stoess, Christian
    Sung, Hana
    Kim, Andrea D.
    Tran, Chelsea
    Reca, Agustina
    Ballatore, Carlo
    Dohil, Ranjan
    Feldstein, Ariel E.
    HEPATOLOGY, 2023, 78 : S1195 - S1196
  • [32] CCN6 improves hepatic steatosis, inflammation, and fibrosis in non-alcoholic steatohepatitis
    Song, Yiran
    Li, Chenyang
    Luo, Yuxin
    Guo, Jinbo
    Kang, Yaxing
    Yin, Fengrong
    Ye, Lihong
    Sun, Donglei
    Yu, Jun
    Zhang, Xiaolan
    LIVER INTERNATIONAL, 2023, 43 (02) : 357 - 369
  • [33] NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
    Harrison, Stephen A.
    Rossi, Stephen J.
    Paredes, Angelo H.
    Trotter, James F.
    Bashir, Mustafa R.
    Guy, Cynthia D.
    Banerjee, Rajarshi
    Jaros, Mark J.
    Owers, Sandra
    Baxter, Bryan A.
    Ling, Lei
    DePaoli, Alex M.
    HEPATOLOGY, 2020, 71 (04) : 1198 - 1212
  • [34] Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH)
    Hussein, Osamah
    Grosovski, Masha
    Schlesinger, Sorina
    Szvalb, Sergio
    Assy, Nimer
    DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (10) : 2512 - 2519
  • [35] COMBINATION THERAPY WITH CILOFEXOR AND FIRSOCOSTAT IMPROVES PLASMA FIBROSIS BIOMARKERS IN PATIENTS WITH ADVANCED FIBROSIS DUE TO NON-ALCOHOLIC STEATOHEPATITIS
    Kowdley, Kris V.
    Kohli, Anita
    Zhu, Kaiyi
    Xu, Jun
    Nandakumar, Madhumitha
    Ishida, Julie
    Watkins, Tim
    Lim, Sharlene
    Malkov, Vlad
    Billin, Andrew
    Noureddin, Mazen
    Loomba, Rohit
    HEPATOLOGY, 2022, 76 : S68 - S69
  • [36] Fibrogenesis and fibrosis in nonalcoholic steatohepatitis
    Di Rocco, P
    Costanzo, M
    Miele, L
    Forgione, A
    Alfei, B
    Rapaccini, G
    Grieco, A
    Gasbarrini, G
    GASTROENTEROLOGY, 2002, 122 (04) : A673 - A673
  • [37] Fibrosis in alcoholic and nonalcoholic steatohepatitis
    Bataller, Ramon
    Rombouts, Krista
    Altamirano, Jose
    Marra, Fabio
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2011, 25 (02) : 231 - 244
  • [38] Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
    Boettcher, E.
    Csako, G.
    Pucino, F.
    Wesley, R.
    Loomba, R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (01) : 66 - 75
  • [39] QUANTITATION OF PLASMA CELLS, CYTOTOXIC T CELLS, AND KUPFFER CELLS/MACROPHAGES WITH HEPATIC FIBROSIS STAGE IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
    Estep, Michael
    Masters, Annie
    Alaparthi, Lakshmi
    Bratthauer, Gary
    Birerdinc, Aybike
    Monge, Fanny
    Sharp, Cassandra
    Tan, Daisong
    Abdelaal, Hala
    Goodman, Zachary
    Younossi, Zobair
    HEPATOLOGY, 2024, 80 : S865 - S865
  • [40] THE ELF™ TEST IMPROVES RISK STRATIFICATION VERSUS HISTOLOGICAL STAGING FOR PREDICTION OF CLINICAL AND HISTOLOGICAL OUTCOMES IN MASH AND ADVANCED FIBROSIS
    Sanyal, Arun
    Fonstad, Rachel
    Brown, Chadwick
    Gee, Matthew
    HEPATOLOGY, 2024, 80 : S658 - S659
12345